Abstract
Introduction
The evolution of nasosinus endoscopes and an improvement in our understanding of nasosinus pathophysiology in chronic sinusitis have revolutionized the treatment of sinus disease. Stammberger' in Europe and Kennedy-in the United States have standardized and popularized the Messerklinger technique described in 1978, which is now accepted worldwide. Although functional endoscopic sinus surgery (FESS) provides good results in cases of chronic nonallergic rhinosinusitis, its results are poor in patients with allergy-associated chronic sinusitis.
According to Stammberger and Posawetz, allergic disease of the upper airway is not a primary indication for FESS.3 They advocate FESS as an adjuvant therapy in patients who do not respond to hyposensitization and antiallergic therapy. In such cases, they stress the need for a limited surgical procedure to treat the stenosis in the middle meatus and ethmoid complex.
Nishioka et al found that the polyp recurrence rate was higher following FESS in allergic patients." Levine reported better results in cases of chronic sinusitis than in cases of polyposis.' Our own experience with FESS in chronic sinusitis reveals that nasal allergy heralds a poor prognosis. A second look into the nasosinus ventilatory physiology, which is considerably altered in post-FESS cases, explains the reason for its failure. Removal of the uncinate process hypothetically exposes the operated ethmoid cavity and the major sinuses to allergens and bacteria-contaminated inspiratory airflow. This leads to allergen exposure to a larger surface area, which causes increased or persistent mucosal disease.
In this article, we stress the need for a proper case selection for FESS, and we emphasize the need to view cases of chronic sinusitis associated with nasal allergy more cautiously and skeptically. We advocate functional endoscopic nasosinus surgery (FENS) as an adjuvant modality of treatment in cases that are refractory to pharmaco-and immunotherapeutic measures. FENS involves the simultaneous endoscopic treatment of the turbinates and septum to relieve the nasal obstruction associated with allergy and a limited sinus surgery that preserves the uncinate process. This modified endoscopic surgery protects the mucosa of the sinuses from allergen exposure during inspiration without compromising the clearance of ethmoidal disease. This technique perhaps favors better ventilation of the sinuses in the more sterile and allergen-free expiratory phase than in the more contaminated and allergen-carrying inspiratory phase. 
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Rationale for FENS
The vertical jet ofinspired air spreads in a wide and gentle curve from the internal nasal valve toward the choanae. During quiet inspiration, the flow becomes laminar at the valve area, and the direction becomes horizontal. Most of the airflow occurs along the middle meatus and floor of the nose, with less turbulence. The conformity of the lateral wall to the shape of the septum tends to keep the passage narrow and of uniform width, thereby promoting laminar flow. This thin laminar flow facilitates the exchange of temperature and humidity between the turbinates and the inspired air." The expired air is more turbulent and flows throughout the nasal cavity. The sinuses are ventilated in the expiratory rather than inspiratory phase. 7 The accompanying diagrammatic representation of airflow during the two phases of respiration in the nasal cavity and sinuses clearly shows the role ofthe uncinate process in directing the inspired air away from the sinuses, thus protecting them (figure 1). The uncinate process probably also directs the expired air into the infundibulum and the maxillary ostium. Inspired air carries allergens and bacteria. Expired air is more sterile and allergen-free because it is "pretreated" by the respiratory mucosa. Thus, the sinuses are normally ventilated by a more sterile and allergen-free air. Moreover, an important and hitherto unrecognized function of the paranasal sinuses is that they provide a continual supply of fresh, 392 uncontaminated mucus to the middle meatus so that mucociliary activity is preserved. ' Removal of the anterior part of the middle turbinate, as suggested by LaMear et aI,9 and the uncinate process exposes the sinuses to the rather contaminated inspired air. This is what hypothetically occurs in post-FESS patients, in whom the area of allergen deposition is greatly enhanced, extending into the sinuses. This might be the reason for the persistent postnasal drip and the increase in respiratory symptoms in post-FESS patients.
Keeping this in mind, the aims of FENS are (1) to preserve the uncinate process and anterior end of the middle turbinate, thereby protecting the sinuses from the contaminated inspired air; (2) to allow better ventilation of the sinuses in the expiratory phase by resecting the inferolateral part of the middle and inferior turbinates, which does not disrupt the laminar inspiratory flow because the conformity between the septum and lateral wall is preserved; (3) to treat sinus disease with a limited resection; and (4) to concomitantly treat the septal deformity via an ultraconservative approach aided by endoscopes.
FENS operative technique
In our study, all but seven FENS patients received local anesthesia. For vasoconstriction and topical anesthesia, each patient's nose was sprayed with 4% lidocaine with 1:25,000 epinephrine. Cottonoid packs soaked in 4% lidocaine with 1:25,000 epinephrine were also placed. The surgical target sites were infiltrated with 2% lidocaine with 1:100,000 epinephrine. In all procedures, 4-mm, 0°a nd 30°nasal telescopes were used. The surgical procedure involved the simultaneous treatment of the pathologic septa, turbinates, and sinuses endoscopically.
Septal correction. After infiltration, ahemitransfixation incision was made. Septal deviations were corrected endoscopically. A hemitransfixation incision was made on the concave side in an S-shaped deviation. However, for a posterior deviation, a C-shaped spur was made on the convex side. The septal flap was elevated. Ultraconservative resection of the septal pathology was performed wheneverindicated. Alignment of the septum was achieved by wedge resection, trimming, or crisscross incisions."
After surgical treatment of the turbinates and the sinuses, the septal flaps were kept apposed and splinted with dental wax plates, which had been sterilized in glutaraldehyde and cut to fit the nasal cavity." These splints were anchored together to the septum by a throughand-through stitch with 2-0 catgut or silk approximately 1.5 to 2 em posterior to the caudal end of the septum.
Turbinoplasty. In all cases, the inferior turbinate was trimmed inferolaterally, and the end that projected toward the nasopharynx was amputated as described by Nayak et al.'? The inferolateral portion of the middle turbinate was also resected in the middle and posterior areas (figure 2). Chemotherapy-Induced Nausea and Vomiting: The following adverse events have been reported in 25%ofadult patients receiving concurrent highly emetogenic cisplatin-based chemotherapy regimens (cisplatin dose 250mgtm'). Central Nervous System: There have been rare reports consistent with, butnotdiagnostic of,extrapyramidal reactions in patients receiving ondansetron.
Hepatic: in 723 patients receiving cyclophosphamide-based chemotherapy in US clinical triais, AST and/or ALT values have been reported to exceed twice theupper limitof normal in approximately 1%to 2%of patients receiving ZOFRAN Tablets. The increases were transient and didnotappear to berelated to dose orduration attherapy. On repeat exposure, similar transient elevations intransaminase values occurred in some courses, butsymptomatic hepatic disease didnotoccur. The role ofcancer chemotherapy in these biochemical changes cannot beclearly determined.
There have been reports of liverfailure and death in patients withcancer receiving concurrent medications including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. The etiology ofthe liverfailure is unclear.
Integumentary: Rash has occur .
Other: Rare cases of .
Observed During Clinical Practice: Inaddition to adverse events reported from clinical trials, the following events have been identified during post-approval use atintravenous formulations of ZOFRAN. Because they are reported voluntarily from a population of unknown size, estimates offrequency cannot bemade. The events have been chosen for inclusion due to a combination oftheir seriousness, frequency of reporting, orpotential causal connection toZOFRAN.
*8ltes of pain Included abdomen, stomach, JOints, ribcage, shoulder.
Pediatric Use: The following were themost commonly reported adverse events inpediatric patients receiving ondansetron (asingie O.I-mg/kg dose for pediatric patients weighing 40kgorless, or4 mgfor pediatric patients weighing more than 40kg)administered intravenously over atleast 30seconds. Rates ofthese events were not significantly different intheondansetron and placebo groups. These patients were receiving multiple concomitant perioperative and postoperative medications. 
GlaxoWellcome
Preiiminary observations in a small number of SUbjects sugest a higher incidence of headache when ZOFRAN ODT Orall . atingTablets aretaken withwater, when compared to without water. General: Flushing, Rare cases of hypersensitivity reactions, sometimes severe (e.g., anaphylaxis/ anaphylactoid reactions, angioedema, bronchospasm, shortness of breath, hypotension, laryngeal edema, stridor) have also been reported. Laryngospasm, shock, and cardiopulmonary arrest have occurred during allergic reactions in patients receiving injectable ondansetron.
Hepatobiliary: Liver enzyme abnormalities Lower Respiratory: Hiccups Neurology: Oculogyric crisis, appearing alone, aswellaswithotherdystonic reactions Skin: Urticaria DRUG ABUSE AND DEPENOENCE: Animal studies have shown that ondansetron is notdiscriminated asa benzodiazepine nordoes it substitute for benzodiazepines in directaddiction studies. OVERDOSAGE: There is nospecific antidote for ondansetron overdose. Patients should bemanaged with appropriate supportive therapy. Individual doses aslarge as150mg andtotaldaily doses aslarge as252mg have been inadvertently administered intravenously without significant adverse events. These doses aremore than 10timestherecommended daily dose.
in addition to theadverse events listed above, Ihefollowing events have been described in thesetting of ondansetron overdose: "Sudden blindness" (amaurosis) of 2 to 3 minutes duration plussevere constipation occurred in onepatient thatwas administered 72 mgof ondansetron intravenously asa single dose.
Hypotension (and faintness) occurred in a patient thattook48 mg of ZOFRAN Tablets. Following intusion of 32 mgoveronlya 4-minute period, a vasovagal episode withtransient second degree heart block was observed. In all instances, theevents resolved completely. Gastrointestinal: Constipation has been reported in 11% of chemotherapy patients receiving multiday ondansetron. Hepatic: in comparative trials in cisplatin chemotherapy patients withnormal baseline values ofaspartate transaminase (AST) and alanine transaminase (ALD, these enzymes have been reported to exceed twice theupper limitof normal in approximately 5%of patients. Iheincreases were transient anddidnotappear to berelated to dose or duration of therapy. Onrepeat exposure, similartransient elevations in transaminase values occurred in some courses, butsymptomatic hepatic disease didnotoccur.
Integumentary: Rash has occurred in approXimately 1% of patients receiving ondansetron. Neurological: There have been rare reports consistent with, butnotdiagnostic of,extrapyramidal reactions in patients receiving ZOFRAN Injection, and rare cases of grand mal seizure. The reiationship to ZOFRAN was unclear.
Other: Rare cases of hypokalemia have been reported. The relationship to ZOFRAN Injection was unclear. Postoperative Nausea andVomiting (PONV): The following adverse events have been reported in patients receiving multiple concomitant perioperative and postoperative medications. Rates ofthese events were notsignificantly different intheondansetron and placebo groups. 
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The concha bullosa was resected laterally. Submucous diathermy was performed at the anterior end of the inferior turbinate-at times even to a polypoidal middle turbinate. Diathermy of the raw stump of the trimmed turbinates helped achieve hemostasis. Too much resection of the middle turbinate was avoided to maintain its stability.
Sinus surgery. Unlike FESS, FENS allows the surgeon to preserve the uncinate process. The anterior ethmoid cells were exenterated to the extent possible by a curved curette and upturned forceps. The maxillary ostium was visualized with a 30°endoscope, usually anteroinferiorly to the bulla ethmoidalis in the hiatus semilunaris. When it was found, it was widened posteriorly and inferiorly. When the maxillary ostium could not be found, a curved spoon or fine cannula was used to palpate and probe the ostium just lateral to the inferior attachment of the uncinate process and inferior to the bulla. If the maxillary ostium still could not be located, the posterior aspect of the uncinate process was partially trimmed with a backward-cutting forceps to expose the natural ostium area ( figure 3) .
The posterior fontanelle was opened with a sickle knife, and the backward-cutting forceps were reintroduced to enlarge the antrostomy to join the natural ostium. A large middle meatal antrostomy was created until the roofof the antrum was well visualized (figure 4). Care was taken to preserve the uncinate process. When an accessory ostium was also found, the bridge of tissue between it and the natural ostium was removed. (An accessory ostium seen through a 0°scope itself should not be confused with the true ostium, which opens near the roof of the antrum.)
When computed tomography (CT) and diagnostic nasal endoscopy found no disease, the ethmoid sinuses were not tively." The bulla was found to be the most constant ethmoidal cell and the key area for approaching either the anterior or the posterior group of air cells. The bulla was first punctured inferomedially and later exenterated with caution after the surgeon identified the lamina papyracea and the roof of the ethmoids. Identification of these structures was very easy via the transbullar approach. Using the fovea, lamina papyracea, and the middle meatal antrostomy as landmarks, the remainder of the ethmoids and sphenoids were exenterated when indicated (figure 5). A diseased frontal sinus and/or recess necessitated exenteration of even a normal bulla for proper access. A 30°scope and an upturned forceps were used between the middle turbinate and lateral wall just posterior to the uncinate process to open the frontal recess and then the frontal sinus. It was not difficult to clear the frontal recess disease and create a frontal sinusotomy despite the uncinate process preservation. Occasionally, a 90°scope was used to visualize the frontal recess better. The posterior ethmoids and sphenoids were exenterated only when indicated.
Dental wax plates were used as a spacer between the middle turbinate and the lateral wall, in the manner described by Nayak et al,13 whenever the development of synechiae was anticipated. Packing of the nasal cavity was not necessary except in three patients, who exhibited an ooze from the resected stump of the inferior turbinate. This was controlled by placing a cottonoid soaked in bismuth iodoform paraffin paste, which was removed after 8 to 12 hours.
Materials and methods
We identified 120 patients with allergy-associated chronic rhinosinusitis who had been treated between January 1993 and December 1996 at Kasturba Hospital in Manipal, India. These patients had not responded to medical treatment. They were prospectively randomized into one of two groups (60 patients in each); one group underwent FESS as described by Stammberger,' and the other underwent FENS.
Sixty-four of these patients were available for a followup of 6 months or more-30 in the FESS group and 34 in the FENS group. Each patient was evaluated by a detailed history, clinical examination, nasal endoscopy, and radiology ofthe paranasal sinuses. None of them had a history suggestive of food allergy. In each case, sinus disease was confirmed by CT. Every patient had a positive allergic skin test, and each either had undergone or were undergoing hyposensitization and other antiallergic therapy. Patients who had frank nasal polyposis on anterior rhinoscopy were excluded from this study.
The two groups were age-and sex-matched. All patients were subjectively evaluated pre-and postoperatively with a visual analog scale. Objective evaluation was performed by nasal endoscopy. A topical budesonide nasal spray was advised for all patients postoperatively for a minimum of 3 months. Maintenance therapy with cromolyn sodium nasal spray or a systemic antihistamine was advocated in most cases, depending on the response. A few patients required intermittent short courses of systemic steroids.
Results
Of the 120 patients, 64 were available for a followup of at least 6 months (range: 6 mo to 6 yr)-30 patients in the FESS group and 34 in the FENS group. All of these patients had symptoms of perennial allergy and chronic sinusitis, and most had headache, anterior nasal dis- Six of the FESS patients underwent septoplasty during a different sitting, while three underwent septal surgery concurrently. The conventional Messerklinger technique was used for all FESS patients, and the extent of ethmoid exenteration was guided by CT. Twenty-four patients underwent middle meatal antrostomy, and six patients underwent a total sphenoethmoidectomy.
All 34 of the FENS patients underwent turbinoplasty, and 22 had a septal correction. All 34 had a middle meatal antrostomy-28 with an ethmoidectomy and 6 without. Ofthe 28 patients who underwent an ethmoidectomy, 22 had an anterior ethmoidectomy, 4 had an anterior and posterior ethmoidectomy, and 2 others had an anterior and posterior ethmoidectomy in addition to a sphenoidotomy.
Subjective evaluation. The criteria for surgical cure in the literature differ widely, from symptomatic improvement to complete resolution. Therefore, the statistical significance of success rates in different studies cannot be compared. We categorized our subjective postoperative results as either resolved, improved, unchanged, or worse (table 2). Our subjective evaluations were aided and documented by comparisons with each patient's pre-and postoperative visual analog scores. The statistical significance of the differences between the numbers of patients whose symptoms had resolved and those whose symptoms had not resolved was calculated according to the X 2 tests with Yates' correction.
The resolution rates for headache, nasal obstruction, and postnasal drip were significantly greater in the post- FENS group than in the post-FESS group. Anterior nasal discharge, sneezing spells, hyposmia, and wheezing were not significantly resolved by either surgery. However, there was a significant difference in favor of FENS in patients with sneezing and wheezing when the percentage of those whose symptoms resolved was combined with the percentage of those whose symptoms improved (psO.05).
Objective evaluation. Postoperative followup evaluation by nasal endoscopy documented the outcomes of both surgeries, and it showed that FENS was clearly superior to FESS (table 3) . However, the poorresponse in the FESS group might have been attributable to a much worse underlying allergy and to the greater extensiveness of the surgery. No orbital complication or cerebrospinal fluid rhinorrhea was encountered during or after either surgery.
Discussion
Messerklinger's endoscopic approach to the nasal sinuses is well established.r':" This procedure involves the removal of the uncinate process, clearance of the ethmoid disease, and the creation of frontal and maxillary sinuso- 
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Inaddition. thefollowing adverse events (2:3% incidence) were reported at dosages of 15-30mg/day in the controlled clinical trials: Headache (11 %), dyspepsia (7%), lacrimation (6%), edema (5%), abdominal pain (4%), amblyopia (4%), vomiting (4%). pharyngitis (3%), hypertension (3%).
The following events were reported withtreated head and neck cancer patients at incidences of 1% to 2% at dosages of 7.5 to 30 mg/day: abnormal vision, conjunctivitis, dysphagia, epistaxis, myalgias, pruritus, rash, sinusitis, tachycardia, taste perversion, tremor, voice alteration.
The foHowing events were reported rarely in treated headand neck cancer patients (<1%):Causal relation Is unknown.
Body odor, hypothermia, mucous membrane abnormality, bradycardia, ECG abnormality, palpitations, syncope, anorexia, increased appetite, esophagitis, gastrointestinal disorder, tongue disorder, leukopenia, lymphadenopathy, anxiety, confusion, depression, abnormal dreams, hyperkinesia, hypoesthesia, nervousness, paresthesias, speech disorder, twitching, increased sputum, stridor, yawning, seborrhea, deafness, eye pain, glaucoma, dysuria, metrorrhagia, urinary impairment.
Inlong-term treatment were two patients withunderlying cardiovascular disease of whom one experienced a myocardial infarct andanother an episode of syncope. The association withdrugis uncertain.
Sjogren's Syndrome Patients: Incontrolled studies, 376patients received pilocarpine, of whom 5% were men and 95% were women. Race distribution was84% Caucasian, 9%Oriental, 3%Black, and 4%ofother origin. Mean age was55 years. The majority of patients were between 40 and 69 years (70%), 16%were70 years and older and 14%were younger than 40years ofage. Ofthese patients, 161/629 (89/376 receiving pilocarpine) were over theageof 65years. The adverse events reported bythose over 65years and those 65years and younger were comparable except fornotable trends torurinary trequency, diarrhea, and dizziness. The incidences of urinary frequency anddiarrhea in the elderly were about double those in the non-elderly. The incidence of dizziness was about three times as high in the elderly as in the non-elderly. These adverse experiences were not considered to be serious. In the 2 placebocontrolled studies, themost common adverse events related to druguse were sweating, urinary frequency, chills, andvasodilatation (flushing). The most commonly reported reason for patient discontinuation oftreatment was sweating. Expected pharmacologic effects ofpilocarpine include the following adverse experiences associated withSAlAGEN® Tablets: SALAGEN® Tablets   (pilocarpine hydrochloride) Brief Summary
Consult package insert for full prescribing information INDICATIONS ANO USAGE: SAlAGEN® Tablets areindicated for 1) the treatment of symptoms of dry mouth fromsalivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment ofsymptoms ofdrymouth in patients withSjogren's syndrome.
CONTRAINDICATIONS: SAlAGEN®Tablets arecontraindicated inpatients with uncontrolled asthma, known hypersensitivity to pilocarpine, and when miosis isundesirable, e.q., inacute iritisand in narrow-angle (angle closure) giaucoma.
WARNINGS:
Cardiovascutar Disease: Patients withsignificant cardiovascular disease maybeunabie tocompensate fortransient changes inhemodynamics or rhythm induced bypilocarpine. Pulmonary edema has been reported asa complication ofpilocarpine toxicity fromhigh ocular doses given foracute angle-closure glaucoma. Pilocarpine shouid beadministered withcaution in and under close medical supervision of patients with significant cardiovascular disease.
Ocular: Ocular formulations of pilocarpine have been reported to cause visual blurring which may result in decreased visual acuity, especially at nightandin patients withcentral lens changes, and tocause impairment of depth perception. Caution should beadvised while driving at nightor performing hazardous activities in reduced lighting.
Pulmonary Disease: Pilocarpine hasbeen reported to increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. Pilocarpine hydrochloride should be administered with caution to andunder close medical supervision in patients withcontrolied asthma, chronic bronchitis, or chronic obstructive pulmonary disease requiring pharmacotherapy.
PRECAUTIONS:
General: Pilocarpine toxicity is characterized byanexaggeration of its parasympathomimetic effects. These may include: headache, visual disturbance, lacrimation, sweating, respiratory distress, gastrointestinal spasm, nausea, vomiting, diarrhea, atrioventricular block, tachycardia, bradycardia, hypotension, hypertension, shock, mental confusion, cardiac arrhythmia, and tremors.
The dose-related cardiovascular pharmacoiogic effects of pilocarpine include hypotension, hypertension, bradycardia, andtachycardia.
Pilocarpine should beadministered withcaution to patients withknown or suspected cholelithiasis or biliary tract disease. Contractions of the gallbladder or biliary smooth muscle could precipitate complications including cholecystitis, cholangitis, andbiliary obstruction.
Pilocarpine may increase ureteral smooth muscle tone and could theoretically precipitate renal colic (or "ureteral reflux"), particularly in patients withnephrolithiasis.
Cholinergic agonists may have dose-related central nervous system effects. This should beconsidered when treating patients withunderlying cognitive or psychiatric disturbances.
Renal Insufficiency: The pharmacokinetics of orally administered pilocarpine in patients withrenal and hepatic disease is notknown.
Information for Patients: Patients should beinformed thatpilocarpine maycause visual disturbances, especially at night, thatcould impair their ability to drive safely.
If a patient sweats excessively while taking pilocarpine hydrochloride and cannot drink enough liquid, the patient should consult a physician. Dehydration may develop.
OrugInteractions: Pilocarpine should beadministered withcaution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances. Drugs with parasympathomimetic effects administered concurrently with pilocarpine would beexpected to result in additive pharmacologic effects. Pilocarpine might antagonize the anticholinergic effects ofdrugs used concomitantly. These effects should be considered when anticholinergic properties may be contributing to thetherapeutic effect of concomitant medication (e.q., atropine, inhaled ipratropium).
While no formal drug interaction studies have been performed, the following concomitant drugs were used inatleast 10%ofpatients ineither or both Sjogren's efficacy studies: acetylsaiicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeorazole, paracetamol, and prednisone.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Nodefinitive long term animal studies have evaluated the carcinogenic potential of pilocarpine. No evidence thatpilocarpine hasthepotential to cause genetic toxicity wasobtained in a series of studies that included: 1) bacterial assays (Salmonella and E. coli) for reverse gene mutations; 2)anin vitro chromosome aberration assay in a Chinese hamster ovary cellline; 3)an in vivo chromosome aberration assay (micronucleus test) in mice; and 4) a primary DNA damage assay (unscheduled DNA synthesis) in rat hepatocyte primary cultures.
Oral administration ofpilocarpine to male andfemale ratsata dosage at 18 The following adverse experiences have been reported rarely withocular pilocarpine: A-V block, agitation, ciliary congestion, confusion, delusion, depression, dermatitis, middle eardisturbance, eyelid twitching, malignantglaucoma, iriscysts, macular hole, shock, and visual hallucination.
MANAGEMENT DFOVERDOSE: Fatal overdosage with pilocarpine has been reported inthescientific literature at doses presumed to begreater than 100 mg in two hospitalized patients. 100 mg of pilocarpine is considered potentially fatal. Overdosage should betreated withatropine titration (0.5mgto 1.0 mg given subcutaneously or intravenously) and supportive measures to maintain respiration andcirculation. Epinephrine (0.3 mg to 1.0 mg, SUbcutaneously or intramuscularly) may also be of value in the presence of severe cardiovascular depression or bronchoconstriction. It is notknown if pilocarpine is dialyzable.
DOSAGE AND ADMINISTRATION:
Head & Neck Cancer Patients:
The recommended initial dose of SAlAGEN® Tablets is one tablet (5 mg) taken three times a day. Dosage should be titrated according to therapeutic response andtolerance. The usual dosage range is upto 3-6 tablets or15-30mgperday. (Not to exceed 2 tablets perdose.) Aithough early improvement may berealized, at least 12 weeks of uninterrupted therapy withSAlAGEN® Tablets maybenecessary to assess whether a beneficial response will beachieved. The incidence ofthemost common adverse events increases withdose. to rethink the pathophysiology of allergy-associated chronic rhinosinusitis, the rationale for FESS in such cases, and the reasons for its failure. As a result of this reconsideration, we began to combine modified conventional surgical techniques (submucosal diathermy and/or a partial inferior turbinectomy) with a judicious use of modified endoscopic sinus surgery to treat such cases. This technique eventually gave rise to the evolution of FENS. Nasal turbinate hypertrophy is often associated with allergy, more so in patients who also have bronchial asthma. Septoturbinal compression is associated with middle turbinate syndrome, and middle turbinate hypertrophy results in an obstruction that alters the normal flow of air and mucus." The inferior turbinates in the allergic nose arethe primary shock organs that cause nasal obstruction." To deal with such turbinates, many techniques have been advocated: intraturbinal steroid injections, submucosal diathermy, surface cautery of the inferior turbinate, bipolar cautery of the turbinate, chemical cautery with agents such as silver nitrate, outfracture of the turbinate, submucosal resection of the inferior turbinate, partial inferior turbinectomy, and endoscopic partial inferior turbinectomy with a powered microcutting instrument.'? Some surgeons perform partial endoscopic middle turbinectomy in all cases as a standard component of FESS.9 LaMear et al, in discussing the impact of middle turbinectomy on the normal nasal physiology, wrote that this procedure is safe and does not cause postoperative atrophic rhinitis. 9 A concha bullosa is trimmed by a partial resection of its lateral aspect. 1 In our series, we performed an inferolateral partial resection and amputation of the posterior end of the inferior turbinate to facilitate the flow of inspiratory air in the inferiormost part of the nasal cavity and to allow for the passage of allergen-free expired air through the middle meatus. The inferolateral trimming of the middle turbinate with preservation of the anterior end helps provide better ventilation of the sinuses during the expiratory phase.
The success of FENS in allergy-associated chronic Allergic rhinitis is one of the most common coexisting conditions in patients with chronic sinusitis, and it is also seen in some patients with bronchial asthma.P-'? In a review of published results of endoscopic sinus surgery, Terris and Davidson documented the presence of allergies in 14 to 58% (mean: 40%) of patients with chronic * MT = middle turbinate.
sinusitis. IS ----------------------------
All patients with allergy-associated chronic sinusitis should be given an adequate course of treatment with pharmaco-and immunotherapy, which are the mainstays of treatment. In patients who do not respond to immunotherapy, the probability of an IgG-mediated food and/or mold allergy should be considered.
Surgical treatment is indicated in refractory cases as the last resort to relieve obstruction and infection. 19 Stammberger and Posawetz advocated a limited endoscopic sinus surgery as an adjuvant treatment.' Such an operation helps to modify minor obstructive anatomic variants, but it has no effect on the allergy. 16, 17 Shambaugh viewed the new sinus operations for allergic rhinitis with great skepticism." Indeed, the efficacy of FESS in allergy-associated chronic rhinosinusitis is not impressive in the literature. Davis et al observed extended postoperative recovery times and decreased antrostomy patencies in patients operated on during a period of high antigen exposure." In a significant study, Nishioka et al found that a higher incidence of polyp recurrence occurred in allergic cases following FESS.4It has also been reported that patients with diffuse rhinosinopathy and primary eosinophilic infiltration are more likely to develop recurrent disease following endoscopic sinus surgery.'?
Allergy associated with chronic rhinosinusitis is seen frequently in our center. Earlier treatment modalities included submucosal diathermy, partial or total inferior turbinectomy, and intraturbinal corticosteroid injections as an adjunct to pharmaco-and immunotherapy. Refractory sinus disease in such cases was treated by conventional intra-and/or extranasal procedures. Our results, unfortunately, never showed that patients experienced a complete relief of symptoms.
When FESS came into vogue, it was overenthusiastically performed, even in cases of allergy-associated chronic rhinosinusitis. Although FESS produced good results in patients with nonallergic rhinosinusitis, it was disappointing in those with allergy-associated chronic rhinosinusitis. rhinosinusitis might be explained by the protection of the sinuses from allergen exposure during the inspiratory phase and the better ventilation of the sinuses in the allergen-free sterile expiratory phase. Long-term success depends on control ofthe primary cause (i.e., the allergy) ratherthan repeated surgeries to treat pathologic changes. Thus, short courses of systemic steroids and maintenance treatment with nasal steroid sprays, cromolyn sprays, mucolytics, anticholinergics, and/or suitable antihistamines help provide long-term relief. Local and systemic decongestants also provide immediate relief of symptoms, but they cannot be used on a long-term basis because of their side effects. 19 Immunotherapy is promising because it provides long-term symptomatic relief, but it does not statistically influence middle meatotomy patency, synechiae formation, or recurrence of polyps following FESS. 4 Although our preliminary findings are encouraging, a larger series over a longer duration is required to determine its efficacy accurately.
In conclusion, FESS is not the panacea for all sinus disorders, and its role has been overemphasized. In allergy-associated chronic rhinosinusitis, FESS actually aggravates allergic symptoms. We found FESS to be more troublesome than beneficial because of the incidence of persistent or even increased postnasal drip. This was probably the result of the increase in mucosal surface area that became available for allergen exposure plus the drying effect of the increased volume of air as a result of overzealous turbinate resection and total ethmoidectomy. FENS, on the other hand, provides a safe and efficient method of relieving obstruction in the nasal passage and osteomeatal complex. At the same time, it protects the sinuses from allergen exposure, ventilating them during an allergen-free expiratory phase. It is not merely a viable alternative in the management of allergy-associated chronic rhinosinusitis, it is a superior alternative.
